The Continuing Role of PSA in the Detection and Management of Prostate Cancer{A figure is presented}

Kurt Miller, Per Anders Abrahamsson, Koichiro Akakura, Frans M J Debruyne, Christopher P Evans, Laurence Klotz

Research output: Contribution to journalArticle

7 Scopus citations


Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy.

Original languageEnglish (US)
Pages (from-to)327-333
Number of pages7
JournalEuropean Urology, Supplements
Issue number3
StatePublished - Mar 2007



  • Prostate cancer
  • PSA
  • PSA doubling time
  • PSA velocity

ASJC Scopus subject areas

  • Urology

Cite this